Sunil A David, 602811 Gill Ave, Lawrence, KS 66047

D459801, Jul 2, 2002

Oct 5, 2001

29/149237

Sunil A. David - Lawrence KS, 66044

2404

D24125, D24124

7199267, Apr 3, 2007

Oct 21, 2005

11/254743

Mark R. Burns - Kenmore WA, US
Sunil A. David - Lawrence KS, US

MediQuest Therapeutics, Inc. - Bothell WA
The University of Kansas - Lawrence KS

C07C 233/01

564152

Small molecule polycationic agents are used to modulate or interrupt biological processes by binding to oligosaccharide-based biomolecules. Compounds that inhibit nitric oxide, TNFα or other immunomodulators are provided and are useful for treating immunological disease and disease of an infectious disorder.

7411002, Aug 12, 2008

Jun 7, 2006

11/447865

Mark R. Burns - Kenmore WA, US
Sunil A. David - Lawrence KS, US
Scott A. Jenkins - Tucson AZ, US

The University of Kansas - Lawrence KS
Mediquest Therapeutics, Inc. - Bothell WA

A61K 31/18
C07C 311/05

514601, 564 82, 564 98

Certain lipophilic polycationic sulfonamides are provided and are useful for treating various diseases or conditions and particularly sepsis.

7662999, Feb 16, 2010

Mar 30, 2007

11/693941

Mark R. Burns - Kenmore WA, US
Sunil A. David - Lawrence KS, US

National Institutes of Health (NIH) - Bethesda MD
The United States of America as represented by the Department of Health and Human Services (DHHS) - Washington DC

C07C 233/01

564152

Small molecule polycationic agents are used to modulate or interrupt biological processes by binding to oligosaccharide-based biomolecules. Compounds that inhibit nitric oxide, TNFα or other immunomodulators are provided and are useful for treating immunological disease and disease of an infectious disorder.

2006012, Jun 8, 2006

Nov 14, 2005

11/271743

Mark Burns - Kenmore WA, US
Sunil David - Lawrence KS, US

MediQuest Therapeutics, Inc. - Bothell WA
The University of Kansas - Lawrence KS

A61K 31/16

514616000, 514626000

Lysine-spermine conjugates with a long-chain aliphatic (C-C) substituent at Rbind and neutralize bacterial lipopolysaccharides. These compounds reduce lethality in a murine model of lipopolysaccharide-induced shock, and may serve as novel leads for developing novel anti-lipopolysaccharide agents for the therapy of Gram-negative sepsis. These compounds are represented by the formula: wherein X is O or H, H; R is a hydrophobic C-Cchain and Y is -NHor -H; and pharmaceutically acceptable salts thereof and prodrugs thereof.

2007019, Aug 23, 2007

Feb 22, 2007

11/709425

Sunil A. David - Lawrence KS, US
Apurba Dutta - Lawrence KS, US

A61K 31/16
A61K 31/13

514625, 514674

Polyamines with varying chain-lengths were evaluated for antimicrobial activity in order to test the hypothesis that these bis-cationic amphipathic compounds may also bind to and permeabilize intact Gram negative bacterial membranes. The compounds were found to possess significant antimicrobial activity and mediated via permeabilization of bacterial membranes. Homologated spermine, bis-acylated with Cor Cchains was found to profoundly sensitize to hydrophobic antibiotics such as rifampicin.

2012029, Nov 22, 2012

May 18, 2012

13/475284

Sunil A. David - Lawrence KS, US
Nikunj M. Shukla - Lawrence KS, US

THE UNIVERSITY OF KANSAS - Lawrence KS

C07D 471/04
A61K 39/39
G01N 21/64
A61P 31/00
C07F 5/02
C07K 17/02
G01N 33/53
C08B 37/00
A61K 39/385
C07D 519/00

4241931, 546 82, 4241841, 435 29, 546 13, 530331, 435 792, 536 551, 544261

The present disclosure provides novel imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof, and methods of making and using such compounds. The present disclosure also provides TLR7 agonists and TLR7/TLR8 dual agonists, probes, tissue-specific molecules, adjuvants, immunogenic compositions, therapeutic compositions, and self-adjuvanting vaccines including the imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof. Derivatives of the imidazoquinoline derived compounds also include dendrimers and dimers of the imidazoquinoline derived compounds, and methods of making and using the dendrimeic and dimeric imidazoquinoline derived compounds. The present disclosure also provides dual TLR2/TLR7 hybrid agonists that include imidazoquinoline derived compounds of the present disclosure.

5998482, Dec 7, 1999

Nov 10, 1998

9/188720

Sunil A. David - Kansas City KS
David C. Morrison - Mission Hills KS

A61K 3116

514626

The present invention describes the ability of synthetic cationic amphiphilic molecules to bind and sequester bacterial lipopolysaccharides and other microbial products that share structural and/or physical-chemical properties with those of LPS. Such cationic amphiphilic molecules have a molecular structure comprised of a linear or branched backbone derived from polymethylenes or alkylamines which bear at the termini two or more protonatable positively charged groups derived from primary-amino. imidazolinium, or N, N'-unsubstituted amidinium or guanidium functions. They also possess one or more lipophilic groups derived from fatty acids or hydrocarbon substituents, attached to the backbone via amide, ester, carbamate, or urethane linkages. The use of these compounds provide low cost, effective therapeutic method for the treatment of sepsis and septic shock.